Skip to content

Clinical research of treatment of atopic dermatitis with FuRui moisturizing cream combining with glucocorticoid topical

Clinical research of treatment of atopic dermatitis with FuRui moisturizing cream combining with glucocorticoid topical

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000030246
Enrollment
Unknown
Registered
2020-02-26
Start date
2020-02-25
Completion date
Unknown
Last updated
2020-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis

Interventions

experimental group:FuRui moisturizing cream combined with Hydrocortisone cream
control group:FuRui moisturizing cream base combined with Hydrocortisone cream

Sponsors

Beijing Friendship Hospital affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged 18-65 years, regardless of gender. 2. Patients with atopic dermatitis who were diagnosed according to the diagnostic criteria of Hanifin&Rajka atopic dermatitis. 3. The diameter of target lesions is 2-10cm, located in the extremities or trunk. 4. The area of skin lesions before treatment is less than 10% of body surface area. 5. The total score of symptoms and signs is more than 5 points. 6. Be able to adhere to the requirements of external use of Furou moisturizer and glucocorticoid, and regular follow-up. 7. Have read the instructions of the subject, agree and sign the written informed consent.

Exclusion criteria

Exclusion criteria: 1. Allergic to experimental drugs. 2. The rash is locally associated with viral, bacterial or fungal infection; 3. Serious liver and kidney diseases, blood diseases, autoimmune diseases, chronic severe infections, diabetes, mental illness, etc.; 4. Malignant tumors or other serious diseases that may interfere with the proper evaluation of efficacy; 5. Topical corticosteroid withdrawal time was less than 1 week; 6. The withdrawal time of systemic corticosteroids and other immunosuppressants (Tripterygium, etc.) is less than 4 weeks. 7. Pregnant and nursing women. 8. Skin lesions on the face and skin folds. 9. Other reasons the researchers considered unsuitable for inclusion.

Design outcomes

Primary

MeasureTime frame
Eczema area and severity index;

Countries

China

Contacts

Public ContactLinfeng Li

Beijing Friendship Hospital affiliated to Capital Medical University

zoonli@sina.com+86 13693620186

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026